Media stories about Brainstorm Cell Therapeutics (NASDAQ:BCLI) have been trending somewhat positive recently, according to Accern. The research firm identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Brainstorm Cell Therapeutics earned a news impact score of 0.11 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 45.4403112318347 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the headlines that may have effected Accern Sentiment’s rankings:
- BCLI: Enrollment in Phase 3 Trial of NurOwn® Continuing on Schedule (finance.yahoo.com)
- Brainstorm Cell Therapeutics (BCLI) Upgraded at ValuEngine (americanbankingnews.com)
- Brainstorm Cell Therapeutics (BCLI) Receives New Coverage from Analysts at HC Wainwright (americanbankingnews.com)
- BrainStorm Cell Therapeutics’ (BCLI) CEO Chaim Lebovits on Q1 2018 Results – Earnings Call Transcript (seekingalpha.com)
- What Should Investors Know About Brainstorm Cell Therapeutics Inc’s (NASDAQ:BCLI) Future? (finance.yahoo.com)
A number of research analysts have weighed in on BCLI shares. Maxim Group set a $9.00 price objective on shares of Brainstorm Cell Therapeutics and gave the company a “buy” rating in a report on Wednesday, March 21st. ValuEngine downgraded shares of Brainstorm Cell Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, March 19th. Finally, HC Wainwright started coverage on shares of Brainstorm Cell Therapeutics in a report on Tuesday. They issued a “buy” rating and a $11.00 price objective on the stock.
Brainstorm Cell Therapeutics traded up $0.23, reaching $4.29, during trading on Friday, according to MarketBeat Ratings. 292,037 shares of the stock were exchanged, compared to its average volume of 105,605. The company has a market cap of $77.59 million, a price-to-earnings ratio of -16.50 and a beta of 1.86. Brainstorm Cell Therapeutics has a twelve month low of $2.88 and a twelve month high of $5.18.
Brainstorm Cell Therapeutics (NASDAQ:BCLI) last issued its earnings results on Monday, May 14th. The biotechnology company reported ($0.12) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.14) by $0.02. analysts predict that Brainstorm Cell Therapeutics will post -0.59 earnings per share for the current year.
Brainstorm Cell Therapeutics Company Profile
Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival.
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.